Back to
Dr Arcadi Cipponi
Conjoint Senior Lecturer

Dr Arcadi Cipponi

2008 - Ph.D in Cellular and Molecular Pathology, University of Parma, Italy.

1998 - Degree in Biological Sciences, University of Milan, Italy.

Medicine & Health
School of Clinical Medicine

Dr Arcadi Cipponi received his degree in Molecular Biology at the University of Milan, Italy. He obtained his PhD in Molecular and Cellular Pathology at the University of Parma, Italy.

In 2006 he moved to the Ludwing Institute of Cancer Research in Brussels where he worked on fundamental aspects of anti-tumor immune response in human melanoma.

 In 2011 he joined the group of Prof. David Thomas at the Peter MacCallum Cancer Centre in Melbourne to study the mechanisms driving adaptive mutagenesis of human cancer cells in response to pharmacologic pressures.

 He is currently Senior Research Officer in the Genomic Cancer Medicine Laboratory at the Kinghorn Cancer Centre in Sydney directed by Prof. David Thomas.

 Dr Cipponi’s interests include:

  • The development of in vitro models to define cancer risks associated with germline mutations in tumour suppressor genes
  • The spatial resolution of transcriptional landscapes in human cancer samples
  • The ex-vivo functional and transcriptional profiling of DNA repair defects in primary human cells

 
Phone
02 9355 5756
E-mail
a.cipponi@garvan.org.au
Location
The Kinghorn Cancer Centre 370 Victoria Street, Darlinghurst, NSW 2010, Australia
  • Journal articles | 2020
    2020, 'MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer', Science
    Journal articles | 2019
    2019, 'A quantitative model to predict pathogenicity of missense variants in the TP53 gene', Human Mutation, 40, pp. 788 - 800, http://dx.doi.org/10.1002/humu.23739
    Journal articles | 2019
    2019, 'Development and validation of a targeted gene sequencing panel for application to disparate cancers', Scientific Reports
    Journal articles | 2016
    Ballinger ML; Goode DL; Ray-Coquard I; James PA; Mitchell G; Niedermayr E; Puri A; Schiffman JD; Dite GS; Cipponi A; Maki RG; Brohl AS; Myklebost O; Stratford EW; Lorenz S; Ahn SM; Ahn JH; Kim JE; Shanley S; Beshay V; Randall RL; Judson I; Seddon B; Campbell IG; Young MA; Sarin R; Blay JY; O'Donoghue SI; Thomas DM, 2016, 'Monogenic and polygenic determinants of sarcoma risk: an international genetic study', The Lancet Oncology, 17, pp. 1261 - 1271, http://dx.doi.org/10.1016/S1470-2045(16)30147-4
    Journal articles | 2014
    Cipponi A; Thomas DM, 2014, 'Stress-induced cellular adaptive strategies: Ancient evolutionarily conserved programs as new anticancer therapeutic targets', BioEssays, 36, pp. 552 - 560, http://dx.doi.org/10.1002/bies.201300170
    Journal articles | 2013
    Mitchell G; Ballinger ML; Wong S; Hewitt C; James P; Young MA; Cipponi A; Pang T; Goode DL; Dobrovic A; Thomas DM; Porceddu S; Gattas M; Neuhaus S; Suthers G; Tattersall M; Tucker K; Lewis C; Carey-Smith R, 2013, 'High Frequency of Germline TP53 Mutations in a Prospective Adult-Onset Sarcoma Cohort', PLoS ONE, 8, http://dx.doi.org/10.1371/journal.pone.0069026
    Journal articles | 2012
    Cipponi A; Mercier M; Seremet T; Baurain JF; Theáte I; Van Den Oord J; Stas M; Boon T; Coulie PG; Van Baren N, 2012, 'Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases', Cancer Research, 72, pp. 3997 - 4007, http://dx.doi.org/10.1158/0008-5472.CAN-12-1377
    Journal articles | 2011
    Cipponi A; Wieers G; Van Baren N; Coulie PG, 2011, 'Tumor-infiltrating lymphocytes: Apparently good for melanoma patients. but why?', Cancer Immunology, Immunotherapy, 60, pp. 1153 - 1160, http://dx.doi.org/10.1007/s00262-011-1026-2
    Journal articles | 2009
    Fontana R; Bregni M; Cipponi A; Raccosta L; Rainelli C; Maggioni D; Lunghi F; Ciceri F; Mukenge S; Doglioni C; Colau D; Coulie PG; Bordignon C; Traversari C; Russo V, 2009, 'Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients', Blood, 113, pp. 1651 - 1660, http://dx.doi.org/10.1182/blood-2008-07-168666
    Journal articles | 2007
    Russo V; Cipponi A; Raccosta L; Rainelli C; Fontana R; Maggioni D; Lunghi F; Mukenge S; Ciceri F; Bregni M; Bordignon C; Traversari C, 2007, 'Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity', Journal of Clinical Investigation, 117, pp. 3087 - 3096, http://dx.doi.org/10.1172/JCI30605
    Journal articles | 2006
    2006, 'The in vivo targeting of tumor antigens to DCs by administration of transduced autologous lymphocytes results in robust and prolonged immunization: Pre-clinical validation and results of a pilot clinical studies of vaccination for metastatic melanoma', Journal of Clinical Oncology, 24, pp. 2525 - 2525, http://dx.doi.org/10.1200/jco.2006.24.18_suppl.2525
    Journal articles | 2005
    Valentinis B; Bianchi A; Zhou D; Cipponi A; Catalanotti F; Russo V; Traversari C, 2005, 'Direct effects of polymyxin B on human dendritic cells maturation: The role of IκB-α/NF-κB and ERK1/2 pathways and adhesion', Journal of Biological Chemistry, 280, pp. 14264 - 14271, http://dx.doi.org/10.1074/jbc.M410791200
    Journal articles | 1999
    Aiuti A; Tavian M; Cipponi A; Ficara F; Zappone E; Hoxie J; Peault B; Bordignon C, 1999, 'Expression of CXCR4, the receptor for stromal cell-derived factor-1 on fetal and adult human lymphohematopoietic progenitors', European Journal of Immunology, 29, pp. 1823 - 1831, http://dx.doi.org/10.1002/(SICI)1521-4141(199906)29:06<1823::AID-IMMU1823>3.0.CO;2-B
    Journal articles | 1999
    Aiuti A; Turchetto L; Cota M; Cipponi A; Brambilla A; Arcelloni C; Paroni R; Vicenzi E; Bordignon C; Poli G, 1999, 'Human CD34+ cells express CXCR4 and its ligand stromal cell-derived factor-1. Implications for infection by T-cell tropic human immunodeficiency virus', Blood, 94, pp. 62 - 73, http://dx.doi.org/10.1182/blood.v94.1.62.413k04_62_73
    Journal articles | 1999
    Arcelloni C; Aiuti A; Cipponi A; Paroni R, 1999, 'High-performance liquid chromatographic purification and capillary electrophoresis quantification of the chemokine stromal cell-derived factor-1', Journal of Chromatography B: Biomedical Sciences and Applications, 729, pp. 369 - 374, http://dx.doi.org/10.1016/S0378-4347(99)00154-1

2020-2021

Tour de Cure Pioneering Research Grant

 

2015-2018

NHMRC research grant

 

2013-2014                  

Foundation Grant, Peter MacCallum Cancer Institute, Melbourne Australia.

 

2006-2010                 

Belgian National Founds for Scientific Research (FNRS)

                                              

One of the main interests of the laboratory is to shed light on the hard-wired genetic and molecular mechanisms that are at the basis of the forces promoting adaptive strategies of human cancer cells in response to pharmacological and physiological stresses.

Additional projects are focused on:

  1. Exploiting pharmacologically-induced synthetic lethal vulnerabilities to enhance therapeutic responses in cancer
  2. the development of a new methodology to spatially resolve transcriptional landscapes in human cancer samples
  3. ex vivo functional and transcriptional profiling of DNA repair defects in primary human cells